Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%
Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.
You may also be interested in...
Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.
Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.
Schering-Plough's launch campaign for desloratadine in the U.K. includes a claim that the antihistamine has decongestant properties.